A Revolutionary Treatment in the Fight Against CKD-related Anemia
The innovative, easy-to-administer oral option that safely treats non-regenerative anemia in cats with chronic kidney disease.
Varenzin-CA1 is the FIRST and ONLY FDA conditionally approved option for the treatment of CKD-related anemia, setting the new standard of care for cats suffering from the debilitating effects of this disease.
• A first of its kind in veterinary medicine, Varenzin-CA1 stimulates a
cat’s body to create its own erythropoietin (EPO)*
• Approved for convenient at-home treatment; no in-clinic injections
needed
• Reasonable expectations of efficacy in minimal side effects¹
• No costly and inconvenient extra-label use of erythropoietin
stimulating agents (ESAs)
*Versus administering with a human EPO product
Indication:
Varenzin-CA1 is indicated for the control of nonregenerative anemia associated with chronic kidney disease (CKD) in cats.
Important Safety Information:
For oral use in cats only. Keep this drug, including used syringes, out of reach of children. Wash hands immediately after use. In case of accidental ingestion, seek medical advice immediately. Women who are pregnant or may become pregnant should administer the product with caution. Varenzin-CA1 should not be administered to cats that are pregnant, lactating or intended for breeding or to cats with known hypersensitivity to molidustat. Use with caution in cats with a history of seizures and in cats predisposed to thromboembolic disease. Hematocrit (HCT) or packed cell volume (PCV) levels should be monitored regularly as polycythemia may result from use of Varenzin-CA1. Varenzin-CA1 has not been evaluated in cats less than 1 year of age. The most common adverse reactions included vomiting, increases in systolic blood pressure and mild transient increase in serum potassium. For full prescribing information please visit bit.ly/3Z7BsrT.
References:
¹Varenzin Freedom of Information Summary, NADA 141-571
Varenzin, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
©2023 Elanco or its affiliates. PM-US-23-1681
18 сен 2023
